Combination therapy in migraine: asset or issue?

References

• Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018 Feb 21;19(1):17. PMID: 29468450; PMCID: PMC5821623.
   PubMed Web of Science ®Google Scholar
• Vosoughi K, Stovner LJ, Steiner TJ, et al. The burden of headache disorders in the Eastern Mediterranean Region, 1990-2016: findings from the global burden of disease study 2016. J Headache Pain. 2019 Apr 25;20(1):40. PMID: 31023215; PMCID: PMC6734477.
   PubMed Web of Science ®Google Scholar
• Dabilgou AA, Dravé A, Kyelem JMA, et al. Frequency of headache disorders in neurology outpatients at Yalgado Ouedraogo university teaching hospital. A 3-month prospective cross-sectional study. SN Compr Clin Med. 2020;2:301–307.
   Google Scholar
• Ali MW, Musami UB, Sa’ad FK, et al. Profile of migraine patients in a developing country: a multicentre study. SN Compr Clin Med. 2020;2:1153–1157.
   Google Scholar
• Goodhew SC. Migraine literacy and treatment in a university sample. SN Compr Clin Med. 2019;1:749–757.
   Google Scholar
• Negro A, Sciattella P, Rossi D, et al. Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache centre. J Headache Pain. 2019 Dec 30;20(1):120. PMID: 31888448; PMCID: PMC6937810.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European headache federation and lifting the burden: the global campaign against headache. J Headache Pain. 2019 May 21;20(1):57. PMID: 31113373; PMCID: PMC6734476.
   PubMed Web of Science ®Google Scholar
• De Matteis E, Guglielmetti M, Ornello R, et al. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother. 2020 Jun;20(6):627–641. Epub 2020 Jun 2. PMID: 32434430
   PubMed Web of Science ®Google Scholar
• Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020 Jun 16;21(1):76. PMID: 32546227; PMCID: PMC7296705.
   PubMed Web of Science ®Google Scholar
• Molina KC, Fairman KA, Sclar DA. Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visits. Drug Healthc Patient Saf. 2018 May 3;10:37–43. PMID: 29760569; PMCID: PMC5937481.
   PubMed Web of Science ®Google Scholar
• Vandenbussche N, Laterza D, Lisicki M, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain. 2018 Jul 13;19(1):50. PMID: 30003412; PMCID: PMC6043466.
   PubMedGoogle Scholar
• Jakate A, Boinpally R, Butler M, et al. Evaluation of the pharmacokinetic interaction of ubrogepant coadministered with sumatriptan and of the safety of ubrogepant with triptans. Headache. 2020 Jun 23;60(7):1340–1350. Epub ahead of print. PMID: 32573795.
   PubMed Web of Science ®Google Scholar
• Pomes LM, Gentile G, Simmaco M, et al. Tailoring treatment in polymorbid migraine patients through personalized medicine. CNS Drugs. 2018 Jun;32(6):559–565. PMID: 29926370.
   PubMed Web of Science ®Google Scholar
• Singh A, Gupta D, Sahoo AK. Acute migraine: can the new drugs clinically outpace? SN Compr Clin Med. 2020;2:1132–1138.
   Google Scholar
• Pellesi L, Do TP, Ashina H, et al. Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache. 2020 Jun;60(6):1056–1065. Epub 2020 May 21. PMID: 32437038
   PubMed Web of Science ®Google Scholar
• Angra M, Bhardwaj A, Sharma A, et al. Is single- drug prophylaxis in migraine prevention a better option than combination therapy? An observational study in a rural tertiary care center in North West India. J Neurosci Rural Pract. 2019 Jul;10(3):479–482. Epub 2019 Oct 7. PMID: 31595120; PMCID: PMC6779569
   PubMed Web of Science ®Google Scholar
• Pellesi L, Do TP, Ashina H, et al. Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache. 2020;60(6):1056–1065.
   PubMed Web of Science ®Google Scholar
• Berman G, Croop R, Kudrow D, et al. Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine [published online ahead of print, 2020 Aug 16]. Headache. 2020. DOI:10.1111/head.13930.
   PubMed Web of Science ®Google Scholar
• Mullin K, Kudrow D, Croop R, et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy [published correction appears in Neurology. Neurology. 2020 May 19;94(20):900. 2020;94(20):e2121-e2125
   Web of Science ®Google Scholar
• Capi M, Gentile G, Lionetto L, et al. Pharmacogenetic considerations for migraine therapies. Expert Opin Drug Metab Toxicol. 2018 Nov;14(11):1161–1167. Epub 2018 Nov 1. PMID: 30362834.
   PubMed Web of Science ®Google Scholar
• Martocchia A, Spuntarelli V, Aiello F, et al. Using INTERCheck® to evaluate the incidence of adverse events and drug–drug interactions in out-and inpatients exposed to polypharmacy. Drugs Real World Outcomes. 2020;7:243–249.
   PubMedGoogle Scholar
• Pomes LM, Guglielmetti M, Bertamino E, et al. Optimising migraine treatment: from drug-drug interactions to personalized medicine. J Headache Pain. 2019 May 17;20(1):56. PMID: 31101004; PMCID: PMC6734220.
   PubMedGoogle Scholar
• Joshi N, McAree M, Klimowich K, et al. Oral candidiasis in a migraine patient taking erenumab and galcanezumab: a case report. SN Compr Clin Med. 2020;2:658–661.
   Google Scholar